MERCK Kommanditgesellschaft auf Aktien
MER
Rank in Stocks
#323
Globally, MERCK Kommanditgesellschaft auf Aktien conducts operations across the... Globally, MERCK Kommanditgesellschaft auf Aktien conducts operations across the healthcare, life science, and electronics sectors. The company is actively involved in the research, development, production, and commercialization of both pharmaceutical and biological prescription medications. These treatments target a range of medical conditions, including those in neurology, immunology, oncology, fertility, and cardiometabolic and endocrine disorders. Furthermore, its life science division furnishes essential products, instruments, and services to support research facilities, pharmaceutical and biotechnology manufacturing, and industrial as well as analytical testing laboratories. Within its electronics segment, MERCK supplies crucial materials for integrated circuits, liquid crystals, organic light-emitting diodes (OLEDs), photoresists, smart antenna systems, and liquid crystal glazing solutions. It also produces specialized effect pigments extensively utilized in applications such as automotive coatings, cosmetics, and various industrial and plastics manufacturing. MERCK maintains strategic partnerships with Pfizer Inc., has an agreement with Novartis AG, and holds license arrangements with Debiopharm International SA and MoonLake Immunotherapeutics AG. Established in 1668, the firm's headquarters are located in Darmstadt, Germany, and it operates as a subsidiary of E. Merck Kommanditgesellschaft.
Share Price
$171.67
Last synced: 2026-07-13
Market Cap
$74.64B
Change (1 day)
0.00%
Change (1 year)
-
Country
DE
Trade MERCK Kommanditgesellschaft auf Aktien (MER)
Category
Healthcare
P/E ratio for MERCK Kommanditgesellschaft auf Aktien (MER)
P/E ratio as of 2026 TTM: 0
According to MERCK Kommanditgesellschaft auf Aktien latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for MERCK Kommanditgesellschaft auf Aktien from 2002 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2025 | 20.43 | -6.71% |
| 2024 | 21.90 | -1.27% |
| 2023 | 22.19 | -6.21% |
| 2022 | 23.65 | -26.78% |
| 2021 | 32.31 | 5.20% |
| 2020 | 30.71 | -11.50% |
| 2019 | 34.70 | -0.21% |
| 2018 | 34.77 | 131.56% |
| 2017 | 15.02 | -43.20% |
| 2016 | 26.44 | -24.31% |
| 2015 | 34.93 | 18.49% |
| 2014 | 29.48 | 25.38% |
| 2013 | 23.51 | -39.54% |
| 2012 | 38.89 | 40.84% |
| 2011 | 27.61 | 34.17% |
| 2010 | 20.58 | -46.78% |
| 2009 | 38.67 | 1.21% |
| 2008 | 38.21 | -94.09% |
| 2007 | 646.52 | 4,065.06% |
| 2006 | 15.52 | -24.49% |
| 2005 | 20.56 | 41.08% |
| 2004 | 14.57 | -46.82% |
| 2003 | 27.40 | 35.02% |
| 2002 | 20.29 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| 55.58 | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | - |
IN
|
|
| 38.98 | - |
CN
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.